Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data
Executive Summary
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.
You may also be interested in...
Novartis Hopes To Breathe New Life Into CAR-T Business With ASCO Myeloma Data
Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.
Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.